Question

【题目】 A drug designed entirely by artificial intelligence is about to enter clinical human trials for the first time. The drug, which is intended to treat obsessive-compulsive disorder ( OCD)(强迫症),was discovered using Al systems from Oxford-based biotech company Exscientia. While it would usually take around four and a half years to get a drug to this stage of development, Exscientia says that by using the Al tools it's taken less than 12 months.

The drug, known as DSP1181, was created by using algorithms (算法)to examine potential compounds (化合物),checking them against a huge database of parameters, including a patient's genetic factors. Speaking to the BBC, Exscientia chief executive Professor Andrew Hopkins described the trials as a “ key milestone in drug discovery “ and noted that there are “ billions” of decisions needed to find the right molecules (分子)for a drug, making their eventual creation a “ huge decision. “ With Al, however, “the beauty of the algorithms is that they are unknowable, so can be applied to any disease.”

We've already seen multiple examples of Al being used to diagnose illness and analyze patient data, so using it to engineer drug treatment is an obvious progression of its place in medicine. But the Al - created drugs do bring about some relevant questions. Will patients be comfortable taking medicine designed by a machine? How will these drugs differ from those developed by humans alone? Who will make the rules for the use of Al in drug research? Hopkins and his team hope that these and a great many other questions will be explored in the trials, which will begin in March.

【1】What is special about the drug designed by Al?

A.It's a better cure for OCD.

B.It has no side effect on humans.

C.Its development takes less time.

D.It doesn't need clinical human trials.

【2】Which is a key factor in creating the drug according to Paragraph 2?

A.Trials.B.Algorithms.

C.Compounds.D.Molecules.

【3】How does Hopkins feel about the way of drug creation?

A.Optimistic.B.Doubtful.

C.Disappointed.D.Puzzled.

【4】What can be the best title for the text?

A.Medical Trials by AlB.An Example in Medical Trials

C.A Creation in Al DevelopmentD.Al - designed Drugs to Be on Trial

Answer 1

【答案】

【1】C

【2】B

【3】A

【4】D

【解析】

这是一篇说明文。一种完全由人工智能设计的药物即将首次进入临床人体试验。这种药物是用牛津生物技术公司Exscientia的人工智能系统制造出的，目的是治疗强迫症。短文介绍了制造这种药的关键因素，人工智能制造药物所带来的一些问题。

【1】细节理解题。根据第二段“While it would usually take around four and a half years to get a drug to this stage of development, Exscientia says that by using the Al tools it's taken less than 12 months.”可知，虽然通常需要四年半的时间才能使药物发展到这个阶段，但埃克西迪亚说，通过使用人工智能工具，只需要不到12个月的时间。所以人工智能设计的药物有什么特别之处在于它的开发时间更短。故选C项。

【2】细节理解题。根据第三段“The drug, known as DSP1181, was created by using algorithms (算法)to examine potential compounds (化合物),checking them against a huge database of parameters, including a patient's genetic factors. Speaking to the BBC, Exscientia chief executive Professor Andrew Hopkins described the trials as a “ key milestone in drug discovery ”可知，这种被称为DSP1181的药物是通过使用算法来检测潜在的化合物，并根据一个庞大的参数数据库（包括患者的遗传因素）来检查这些化合物的。Exscientia首席执行官安德鲁霍普金斯教授在接受英国广播公司（BBC）采访时称，这些试验是“药物发现的关键里程碑””,所以算法是制造药物的关键因素。故选B项。

【3】推理判断题。根据倒数第二段“With Al, however, “the beauty of the algorithms is that they are unknowable, so can be applied to any disease.” 然而，对于人工智能来说，“算法的优点在于它们是不可知的，因此可以应用于任何疾病。最后一段“Hopkins and his team hope that these and a great many other questions will be explored in the trials, which will begin in March.”可知，霍普金斯和他的团队希望，这些问题和其他许多问题将在3月开始的试验中得到探索。由此判断出，霍普金斯对药品制造的方式持乐观的态度。故选A项。

【4】主旨大意题。一种完全由人工智能设计的药物即将首次进入临床人体试验。这种药物是用牛津生物技术公司Exscientia的人工智能系统发现的，目的是治疗强迫症。短文介绍了制造这种药的关键因素，人工智能制造药物所带来的一些问题。所以短文最佳的标题为“人工智能设计的药物即将进入临床人体试验”。故选D项。